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Abstract
 
T regulatory (Tr) cells are essential for the induction of peripheral tolerance. Several types of Tr
cells exist, including CD4
 
 
 
 T cells which express CD25 constitutively and suppress immune
responses via direct cell-to-cell interactions, and type 1 T regulatory (Tr1) cells, which function
via secretion of interleukin (IL)-10 and transforming growth factor (TGF)-
 
 
 
. The relationship
between CD25
 
 
 
CD4
 
 
 
 T cells and Tr1 cells remains unclear. Here, we demonstrate at the
clonal level that Tr1 and CD25
 
 
 
CD4
 
 
 
 T cells are two distinct subsets of regulatory cells with
different cytokine production profiles. Furthermore, CD25
 
 
 
CD4
 
 
 
 T cells can be rendered an-
ergic by IL-10 and differentiated into Tr1 cells in the absence of CD25
 
 
 
CD4
 
 
 
 T cells. Cloned
human CD25
 
 
 
CD4
 
 
 
 T cell populations are heterogeneous and only a subset of clones contin-
ues to express high levels of CD25 and is suppressive. The intensity of CD25, cytotoxic T lym-
phocyte antigen (CTLA)-4, and glucocorticoid-induced tumor necrosis factor (TNF) receptor
expression correlates with the suppressive capacity of the T cell clones. None of the
CD25
 
 
 
CD4
 
 
 
 T cell clones with suppressive function produce IL-10, but all produce TGF-
 
 
 
.
Suppression mediated by CD25
 
 
 
CD4
 
 
 
 T cell clones is partially dependent on TGF-
 
 
 
, but not
on constitutive high expression of CD25. Together these data indicate that naturally occurring
human CD25
 
 
 
CD4
 
 
 
 T cells are distinct from IL-10–producing Tr1 cells.
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Introduction
 
Active suppression by T regulatory (Tr)
 
*
 
 cells is essential
for induction of tolerance to both self and foreign antigens
in vivo. Various subsets of Tr cells have been described and
much effort has been focused on understanding their on-
togeny, function, and mechanisms of action. Within the
CD4
 
 
 
 T cell subset, at least three different types of cells
with suppressive function may exist: CD25
 
 
 
CD4
 
 
 
 T cells
(1, 2), type 1 T regulatory (Tr1) cells (3), and Th3 cells (4).
These cell types appear to be distinguishable based on their
cytokine production profile, and their ability to suppress
immune responses via direct cell-to-cell interactions or se-
cretion of immunosuppressive cytokines. However, the re-
lationship between these different types of CD4
 
 
 
 Tr cells is
unclear (3, 5, 6).
Tr1 cells were initially defined in studies of CD4
 
 
 
 T
cells which had been activated in the presence of IL-10 and
rendered anergic (7). Analysis of these anergic T cell popu-
lations at the clonal level showed that they contained a sub-
set of T cell clones (Tr1 cells) which possessed a unique cy-
tokine production profile (8). The Tr1 cells produced high
levels of IL-10 and TGF-
 
 
 
, moderate amounts of IFN-
 
 
 
and IL-5, but little or no IL-2 or IL-4. These data indicate
that IL-10–anergized CD4
 
 
 
 T cells contained the precur-
sors of Tr1 cells, and that IL-10 was a critical factor for
their differentiation. Importantly, Tr1 cells were shown to
be involved in down-regulation of immune responses in
vitro and in vivo, via the production of the immunosup-
pressive cytokines IL-10 and TGF-
 
 
 
 (3).
Another subset of CD4
 
 
 
 Tr cells (Th3 cells) was identi-
fied in studies of oral tolerance. In mice that were orally
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tolerized to myelin basic protein, Th3 cells suppressed in-
duction of EAE via a TGF-
 
 
 
–dependent mechanism (9).
In addition, oral treatment of multiple sclerosis patients
with myelin basic protein (MBP) and proteolipid protein
(PLP) resulted in the generation of MBP or PLP-specific
Th3 cells that secreted TGF-
 
 
 
 (10). Th3 cells also pro-
duced variable amounts of IL-10 and IL-4 (4), and IL-4
was shown to be a key factor for the differentiation of Th3
cells, in contrast to Tr1 cells (11, 12).
In addition to Tr1 and Th3 cells, CD4
 
 
 
 T cells that con-
stitutively express the IL-2R
 
 
 
 (CD25) possess potent
suppressive properties in vitro and in vivo (1, 2).
CD25
 
 
 
CD4
 
 
 
 T cells are generated in the thymus, and are
thought to arise via “altered negative selection” by self-
peptides (6). Although CD25
 
 
 
CD4
 
 
 
 T cells require activa-
tion via the TCR to exert their regulatory function, once
activated, their suppressive activity is antigen nonspecific,
thus, Tr1 and Th3 cells, these cells mediate bystander sup-
pression in vivo (4, 8, 13). The suppressive activity of
CD25
 
 
 
CD4
 
 
 
 T cells is related to their ability to inhibit
IL-2 production and promote cell-cycle arrest in both CD4
 
 
 
and CD8
 
 
 
 T cells, via a mechanism which remains to be
defined, but requires direct cell-to-cell contact and may in-
volve signals through CTLA-4 and/or glucocorticoid-
induced TNF receptor (GITR; references 14–17).
CD25
 
 
 
CD4
 
 
 
 T suppressor cells have recently been
identified in human peripheral blood and thymus (18–24).
Like their mouse counterparts, human CD25
 
 
 
CD4
 
 
 
 T
cells are anergic, and strongly suppress the proliferative re-
sponses of both naive and memory CD25
 
 
 
CD4
 
 
 
 T cells in
response to alloantigens or polyclonal activation. Pure pop-
ulations of human CD25
 
 
 
CD4
 
 
 
 T cells contain both
CD45RO
 
 
 
 and CD45RO
 
 
 
 cells, but the suppressive ac-
tivity is enriched in the CD45RO
 
 
 
 memory fraction (18).
The role of cytokines in the suppressive effects mediated
by CD25
 
 
 
CD4
 
 
 
 Tr cells, and thus their relationship to
Tr1 and Th3 cells, is highly controversial. Some studies
failed to detect production of IL-10 and/or TGF-
 
 
 
 by hu-
man CD25
 
 
 
CD4
 
 
 
 T cells (21, 24), whereas others clearly
showed secretion of these cytokines in response to a variety
of stimuli (19, 20, 22). Interestingly, when activated by al-
loantigens, CD25
 
 
 
CD4
 
 
 
 T cells produced IL-10, TGF-
 
 
 
,
low levels of IFN-
 
 
 
, but no IL-4 or IL-2, a profile of cyto-
kine production which was remarkably similar to that of
Tr1 cells (19). Nevertheless, neither IL-10 nor TGF-
 
 
 
seemed to be directly required for their in vitro suppressive
effects (18, 19, 23, 24). Furthermore, although mouse
CD25
 
 
 
CD4
 
 
 
 T cells secreted more IL-10 than CD25
 
 
 
CD4
 
 
 
 T cells (25), their suppressive function appeared to
be independent of IL-10, as CD25
 
 
 
CD4
 
 
 
 T cells isolated
from mice genetically deficient for IL-10 retained their
suppressive capacity in vitro and in vivo in a model of au-
toimmune gastritis (2, 26). In addition, in vitro studies
failed to show reversal of suppression by anti–TGF-
 
 
 
 mAbs
in the presence or absence of anti–IL-10 mAbs (26, 27). Fi-
nally, CD25
 
 
 
CD4
 
 
 
 T cells from TGF-
 
 
 
1
 
 
 
/
 
 
 
 mice were
fully suppressive in vitro, and target cells which were ge-
 
netically altered to be unresponsive to TGF-
 
 
 
 were suscep-
tible to suppression mediated by CD25
 
 
 
CD4
 
 
 
 T cells (28).
These data, suggesting that IL-10 and TGF-
 
 
 
 are dis-
pensable, are hard to reconcile with recent studies in the
mouse indicating that naturally occurring CD25
 
 
 
CD4
 
 
 
 T
cells prevent inflammatory bowel disease via an IL-10 and/
or TGF-
 
 
 
–dependent mechanism (16, 29). In addition, un-
like their wild-type counterparts, CD25
 
 
 
CD45RB
 
low
 
CD4
 
 
 
T cells from IL-10–deficient mice fail to protect from a
CD45RB
 
high
 
CD4
 
 
 
 T cell–induced wasting disease (30).
Furthermore, Nakamura and colleagues have recently pro-
posed that TGF-
 
 
 
 produced by CD25
 
 
 
CD4
 
 
 
 T cells, and
bound to their cell surface, is the major mechanism by
which murine CD25
 
 
 
CD4
 
 
 
 T cells suppress T cell re-
sponses (31). Recently, membrane-bound TGF-
 
 
 
 has also
been reported to contribute to the suppressive activity of
human CD25
 
 
 
CD4
 
 
 
 thymocytes (32).
The large body of controversial data, mostly regarding
the cytokines produced by CD25
 
 
 
CD4
 
 
 
 T cells and their
role in suppression function, together with the observation
that human CD25
 
 CD4  T cells and Tr1 cells appeared
remarkably similar in many aspects (3), prompted us to
reexamine the potential relationship between IL-10– and
TGF- –producing Tr1 cells and naturally occurring CD25 
CD4  T suppressor cells at the clonal level.
Materials and Methods
Induction of Anergy by IL-10. Total PBMCs, or PBMCs de-
pleted of CD25  cells by incubation with anti-CD25-coupled
microbeads (Miltenyi Biotech) and passage over an LD-depletion
column (Miltenyi Biotech) were used as responders. Depleted
cells were routinely 97–100% CD25  as assessed by FACS® anal-
ysis. Primary MLRs were performed as described previously (7)
by culture of 5   105 responder cells together with 5   105 irra-
diated (6,000 RADS) CD3-depleted stimulator cells in 1 ml of
X-vivo 15 medium (Biowhittaker), supplemented with 10% FCS
(Mascia Brunelli), 1% pooled AB human serum (Biowhittaker),
and 100 U/ml penicillin/streptomycin (Bristol-Myers Squibb), in
24-well plates, and in the absence or presence of IL-10 (100
U/ml, a kind gift from Schering-Plough, Kenilworth, NJ). For
analysis of primary proliferation, parallel cultures were performed
in 96-well round bottom plates (105 responder cells plus 105 stim-
ulator cells in 200  l) and after 4 d, wells were pulsed for 16 h
with 1  Ci/well [3H]thymidine (Amersham Biosciences). For
secondary MLRs, cells were harvested after 10 d, washed, and 105
cells/well were replated alone, or in the presence of 105 cells/well
of freshly prepared irradiated and CD3-depleted stimulator cells.
After 2 d, wells were pulsed for 16 h with [3H]thymidine.
Differentiation of Tr1 Cells. CD4  T cells were purified from
PBMCs by negative selection using the Untouched CD4  T cell
isolation kit (Miltenyi Biotech), according to the manufacturer’s
instructions. CD25  cells were depleted as described above, and
the resulting CD4 CD25  T cells were routinely 97–100% pure.
CD4 CD25  T cells were activated by culture with irradiated
(7,000 RAD) L-cell transfectants expressing hCD32 (FC RII),
hCD58 (LFA-3) and hCD80 (33), and 100 ng/ml of anti-CD3
(OKT3; Orthoclone) in X-vivo 15 medium supplemented with
10% FCS, 1% human serum, 100 U/ml penicillin/streptomycin,
rhIL-2 (100 U/ml; Chiron Corp.), and rhIL-15 (1 ng/ml; R&D1337 Levings et al.
Systems) in the absence or presence of IL-10 (100 U/ml) and
rhIFN-  2b (5 ng/ml; PeproTech), as described previously (33).
At day 7, T cells were collected, washed, counted, and restimu-
lated under identical conditions for an additional 7 d. At day 14
of in vitro culture, cells were collected, washed, counted, and
analyzed for their profile of cytokine production and proliferative
capacity.
Intracellular cytokines were detected by flow cytometry as de-
scribed previously (33). Briefly, 106 T cells/ml were stimulated
with immobilized anti-CD3 (10  g/ml) and soluble anti-CD28
(1  g/ml) mAbs (BD Biosciences) in complete medium. After
3 h of activation, brefeldin A (10  g/m; Sigma-Aldrich) was
added. After a total of 6 h of activation, T cells were collected,
washed, fixed, and permeabilized. Permeabilized T cells were in-
cubated with PE-labeled anti–hIL-4, anti–hIL-2 or anti–hIL-10,
and FITC-coupled anti–hIFN-  (all antibodies were obtained
from BD Biosciences) and analyzed using a FACScan™.
Polarized T cells were tested for their ability to suppress the
proliferation of naive CD4  T cells to alloantigens (33). Autolo-
gous CD4  T cells, which were cryopreserved at the start of the
experiment, were cultured (50,000 cells/well) together with irra-
diated, allogeneic CD3-depleted PBMCs (50,000 cells/well), in
the absence or presence of polarized T cells (100,000, 50,000, or
25,000 cells/well), in a final volume of 200  l of complete me-
dium. After 4 d, wells were pulsed for 16 h with 1  Ci/well
[3H]thymidine.
Cloning of Human CD25 CD4  T Cells. CD4  T cells were
purified from PBMCs by positive selection with anti-CD4–cou-
pled microbeads (Miltenyi Biotech). After isolation of CD4  T
cells, CD25  cells were stained with FITC-coupled anti-CD4
and PE-coupled anti-CD25 mAbs (BD Biosciences) and CD25 
and CD25  cells were purified by FACS®-sorting on a FAC-
Star™. CD25 CD4  and CD25 CD4  T cells were subse-
quently cloned at 1 cell/well in 96–well round bottom plates in
the presence of an allogeneic feeder-cell mixture consisting of
5   105 PBMCs/ml (irradiated 6,000 RADS), 5   104 JY cells/ml
(irradiated 10,000 RADS), and 0.05  g/ml PHA (Roche). All
cultures were performed in X-Vivo 15 medium supplemented
with 5% pooled human serum, and 100 U/ml penicillin/strepto-
mycin. After 3 d, IL-2 (40 U/ml) was added. After 8 d, one 96-
well plate from each cloning was pulsed overnight with [3H]thy-
midine in order to determine the total number of wells with
proliferating cells (the cloning efficiency). At day 14, growing
wells were picked and restimulated with an allogeneic feeder-cell
mixture consisting of 106 irradiated PBMCs/ml, 105 irradiated
JY cells/ml, 0.1  g/ml PHA, and 100 U/ml IL-2. Clones were
split as necessary, and restimulated as above every 14 d. The me-
dium was replenished every 3–5 d. Clones were used for experi-
ments between days 10 and 14 after restimulation (i.e., in the
resting phase).
Proliferation and Suppression of T Cells. To analyze the prolif-
erative capacity of T cell clones in response to polyclonal activa-
tion, 96-well round-bottom plates (Costar) were coated over-
night at 4 C with anti-CD3 mAbs (10  g/ml) in 0.1 M Tris, pH
9.5, and washed three times with PBS. T cell clones were plated
at an initial density of 2   105 cells/ml (40,000 cells/well) in a fi-
nal volume of 200  l of medium in the absence or presence of
IL-2 (100 U/ml). To test the proliferative response to cytokines,
T cell clones were plated as described above in the absence or
presence of IL-2 (100 U/ml), IL-15 (10 ng/ml, R&D Systems),
or IL-2 and IL-15. To test for the capacity of T cell clones to sup-
press the proliferation of autologous CD4  T cells, CD4  T cells
were purified from autologus PBMCs by positive selection
(Miltenyi Biotech) and stimulated with anti-CD3 mAbs which
had been immobilized on plastic (1  g/ml) or bound to alloge-
neic CD3-depleted PBMCs (irradiated 6,000 RADS; 0.5  g/
ml). CD4  T cells (40,000 cells/well) were cultured alone, or in
the presence of a 1:1 ratio of T cell clones in a final volume of
200  l of complete medium in 96-well round-bottom plates. In
some cultures anti–IL-10R (10  g/ml, 3F9; BD Biosciences)
and/or anti-TGF-  (10  g/ml, 1D11; R&D Systems) mAbs
were added. After the indicated time, wells were pulsed for 16 h
with 1  Ci/well [3H]thymidine. Cells were harvested, and
counted in a scintillation counter.
Retroviral Constructs and Transduction of T Cell Clones. The
Moloney murine leukemia virus-based vector encoding the hu-
man CD25 (LCD25S N) under control of the LTR and the low
affinity nerve growth factor (NGF) receptor under control of the
SV40 promoter was generated from the LXS N vector (34). Sta-
ble Am12-based cell lines producing LCD25S N or LXS N
were established. Transduction of T cell clones was performed
48 h after restimulation by two successive rounds of infection on
retronectin-coated plates as described previously (35). Transduced
cells were purified after staining with anti-NGFR mAbs and sort-
ing by FACS®. After expansion, T cell clones which were trans-
duced with control vectors, or vectors encoding hCD25 were
used in suppression assays as described above.
ELISAs. T cell clones (106 cells/ml) were stimulated with
immobilized anti-CD3 mAbs (10  g/ml) and anti-CD28 (1  g/
ml), and supernatants were collected after 24 h for IL-2, 48 h for
IL-4, IL-5, IL-10, and IFN-  and 72 h for TGF- . Levels of
TGF-  in acidified supernatants were determined by capture
ELISA according to the manufacturer’s instructions (R&D Sys-
tems). Levels of IL-2, IL-4, IL-5, IL-10, and IFN-  were deter-
mined either by capture ELISA (BD Biosciences) or by the cyto-
metric bead array kit (CBA; BD Biosciences), according to the
manufacturer’s instructions. A direct comparison of capture
ELISA and CBA demonstrated that the two methods were highly
comparable in terms of the amount of cytokine detected in the
supernatant. The limits of detection were as follows: IL-2, 20 pg/
ml; IL-4, 20 pg/ml; IL-5, 20 pg/ml, IL-10, 20 pg/ml; IFN- , 60
pg/ml; TGF- , 60 pg/ml.
FACS® Staining. Immunofluorescence analysis was per-
formed on resting T cell clones. Analysis of the expression of in-
tracellular CTLA-4 was performed as described previously (19).
Expression of GITR was determined by staining with an anti-
GITR mAb (R&D Systems) followed by a secondary goat anti–
mouse Ab coupled to PE (Caltag). For detection of membrane-
bound TGF- , CD4  T cells were purified from PBMCs by
negative selection (Miltenyi Biotech), and were stained with anti-
CD25 mAbs coupled to PE (BD Biosciences). CD25  and
CD25 CD4  T cells were then purified either by FACS® sort-
ing, or following incubation with anti-PE–coupled microbeads
by positive selection (Miltenyi Biotech). Purified T cells, or total
PBMCs, were subsequently stained with a biotinylated-chicken-
polyclonal IgY anti-TGF-  Ab (R&D Systems; reference 31).
After washing, cells were stained with streptavidin TRI-color
(Caltag), and analyzed by FACS®.
TCR V  Spectratyping. Total RNA was extracted from
CD25 CD4  T cell clones with Eurozol (Euroclone) and 1  g
of RNA was reverse transcribed into cDNA. V  spectratyping
was performed as described previously (36). Fluorescent PCR
products were analyzed using a Fluorimager and ImageQuant
software (Molecular Dynamics).
Statistical Analysis. All analysis for statistically significant differ-
ences was performed with Student’s paired t test. P values  0.051338 Human CD25 CD4  T Cell Clones
were considered significant. All cultures were performed in tripli-
cate and error bars represent the SD unless otherwise indicated.
Results
Induction of Anergy by IL-10 Does Not Require CD25 CD4 
T Cells. We have previously shown that activation of T
cells in the presence of IL-10 not only inhibits the primary
proliferative response, but also results in the induction of
long-lasting antigen-specific unresponsivess (7). Impor-
tantly, IL-10–anergized cells contained the precursors of
Tr1 cells, as cloning under conditions which reversed the
anergic state resulted in the isolation of Tr1-cell clones
which suppressed immune responses in vitro and in vivo
(8). To investigate whether CD25 CD4  T cells may rep-
resent the precursors of Tr1 cells, we first examined
whether these cells were required for IL-10–mediated inhi-
bition of primary proliferative responses to alloantigens or
induction of unresponsiveness in secondary responses.
MLRs were performed in parallel with either total PBMCs
or PBMCs which had been depleted of CD25  cells, as re-
sponder cells. Depletion of CD25  cells resulted in a purity
of CD25  cells  97%. No significant differences in the
ability of IL-10 to inhibit proliferation in primary responses
or induce unresponsiveness in secondary MLRs, were ob-
served between cultures performed in the presence or ab-
sence of CD25 CD4  T cells (Fig. 1, A and B).
In Vitro Differentiation of IL-10–producing Tr1 Cells from
CD25 CD4  T Cells. Activation of naive CD4  T cells
from cord blood or peripheral blood with anti-CD3
mAbs, cross-linked onto L-cells expressing human CD32,
CD58, and CD80, in the presence of IL-10 and IFN- ,
resulted in T cell lines containing IL-10–producing cells
which suppressed antigen-specific responses in vitro (33).
To further investigate whether CD25 CD4  T cells may
represent the precursors of IL-10–producing CD4  T
cells, or be required for the in vitro differentiation of IL-
10–producing cells, CD4  T cells depleted of CD25  cells
were tested in this in vitro differentiation system (33). As
shown in Fig. 2 A, a significant increase in IL-10–produc-
ing cells was observed in cultures of CD25 CD4  T cells
which had been differentiated in the presence of IL-10 and
IFN- , in comparison to cultures in the absence of polar-
izing cytokines. Importantly, as Tr1 cells also produce
IFN-  (8, 33), a majority of the IL-10–producing cells also
produced IFN- . When data from five independent ex-
periments were combined, we observed a significant in-
crease in the percentage of cells expressing IL-10, and
expressing both IL-10 and IFN- , in cultures of
CD25 CD4  T cells differentiated in the presence of IL-
10 and IFN- , in comparison to control cultures of
CD25 CD4  T cells differentiated in the absence of these
cytokines (Fig. 2 B). Cultures of CD25 CD4  T cells dif-
ferentiated with IL-10 and IFN-  also displayed a signifi-
cant reduction in the number of IL-4–producing cells,
while the numbers of IL-2 and IFN- –producing cells
were equivalent to those observed in the absence of IL-10
and IFN- . Thus, similarly to CD4 CD45RO  T cells
(33), CD25 CD4  T cells from peripheral blood can dif-
ferentiate into IL-10–producing Tr1 cells in the presence
of IL-10 and IFN- .
To demonstrate that CD25 CD4  T cells differentiated
with IL-10 and IFN-  displayed suppressive function, we
tested their ability to regulate the proliferation of autolo-
gous CD4  T cells in response to alloantigens. As shown in
Fig. 2 C, cells from cultures performed in the absence of
polarizing cytokines did not suppress proliferation in a pri-
mary MLR. In contrast, addition of cells from cultures
which had been differentiated with IL-10 and IFN-  re-
sulted in a dose-dependent suppression of proliferation.
The average percent inhibition of primary MLRs with dif-
ferent ratios of cells from five independent experiments is
shown in Fig. 2 D. When CD25 CD4  T cells, which had
been differentiated with IL-10 and IFN- , were added at a
2:1 or 1:1 ratio (polarized:naive), a consistent and highly
significant suppression was observed. A less significant and
more variable reduction in proliferation was observed
when cells were added at a 1:2 ratio.
Isolation and Characterization of Human CD25 CD4  T
Cell Clones. CD25bright T cells were purified by FACS®
sorting from peripheral blood CD4  T cells. The resulting
CD25bright and CD25  populations were 98 and 99% pure,
respectively (Fig. 3 A), and were cloned by limiting dilu-
tion, as described in Materials and Methods. The CD25 
CD4  T cells had a cloning efficiency of 42%, whereas the
CD25 CD4  T cells had a lower cloning efficiency of
10.2%. 120 CD25 CD4  and 40 CD25 CD4  T cell
clones were isolated and expanded for analysis. The TCR
usage of 20 clones which were repeatedly tested in the
present study was determined by TCR V  spectratyping
(36). This analysis revealed that each T cell clone tested ex-
pressed a single V  and confirmed their clonal origin. In
Figure 1. IL-10–induced anergy does not depend on the presence of
CD25 CD4  T cells. Total PBMCs or PBMCs depleted of CD25  cells
were stimulated with irradiated CD3-depleted allogeneic APCs for 10 d
in the absence or presence of IL-10 (100 U/ml). After 10 d, cells were
harvested and left unstimulated (cells) or restimulated with the same allo-
geneic APCs in the absence of IL-10 (cells   stim). After 48 h of culture,
[3H]thymidine was added for an additional 16 h. One representative sec-
ondary MLR out of four performed shown in panel A. In B, the average
percent inhibition of proliferation induced by IL-10 in primary (I ) and
secondary (II ) MLRs performed with total or CD25  PBMCs as re-
sponder cells from four independent experiments is shown.1339 Levings et al.
addition, all suppressive clones expressed different V 
chains (data not depicted).
CD25 CD4  T cell clones in the resting phase displayed
a heterogeneous expression of CD25 (Fig. 3 B). Approxi-
mately half of the clones remained 98–100% positive for
CD25, and had a high mean fluorescence intensity (MFI).
The other clones contained a significant number of CD25 
cells and displayed a lower MFI. T cell clones derived from
CD25 CD4  T cells consistently contained a low percent-
age of CD25  cells in the resting phase and consequently
had a low MFI for CD25 (data not depicted).
Similar to the heterogeneity observed in the expression
of CD25, the CD25 CD4  T cell clones were also hetero-
geneous in their proliferative capacities. The majority of
the clones tested (58/72, 80%) were anergic and failed to
proliferate in response to anti-CD3 mAbs, but showed
good proliferative responses when activated by anti-CD3
mAbs in the presence of IL-2. The remaining clones (14/
72, 20%) proliferated significantly in response to anti-CD3
mAbs even in the absence of IL-2. A representative subset
of the 72 clones tested is shown in Fig. 3 C. As expected,
the majority ( 90%) of T cell clones which originated
from CD25 CD4  T cells proliferated well in response to
anti-CD3 mAbs, in the absence of IL-2 (data not depicted).
We previously reported that Tr1-cell clones are prefer-
entially responsive to cytokines, and in particular to IL-15,
in comparison to proliferation after TCR-mediated activa-
tion (12). To further address their possible relationship with
Tr1 cells, we determined the ability of CD25 CD4  T cell
clones to proliferate in response to cytokines. Some clones
(no. 2, 6, 87, and 89) proliferated well in response to both
IL-2 and/or IL-15 (Fig. 3 D). In contrast, others (no. 18,
21, 22, and 42) failed to proliferate in response to IL-2, IL-
15, or the combination, in the absence of TCR-mediated
activation (Fig. 3 D, and data not depicted). Thus, the
CD25 CD4  T cell clones were also heterogeneous in
terms of their response to IL-2 and/or IL-15.
Suppressive Activity of CD25 CD4  T Cell Clones.
The heterogeneity of CD25 CD4  T cell clones, in terms
of expression of CD25 and proliferation, suggested that
some cells within the CD25brightCD4  population of PBMCs,
may not be suppressor cells, and that a proportion are acti-
vated Th cells. To test this hypothesis we performed in
vitro suppression assays with a total of 44 CD25 CD4  T
cell clones. Indeed, as shown in Fig. 4, only a subset of the
CD25 CD4  T cell clones was able to suppress the prolif-
erative response of autologous CD4  T cells in response to
anti-CD3 mAbs cross-linked on T cell–depleted PBMCs
(Fig. 4 A) or immobilized on plastic (Fig. 4 B). All T cell
clones which consistently inhibited the proliferation of the
naive CD4  T cells by more than 20% were considered
suppressive. Activation with immobilized anti-CD3 mAbs
in the absence of APCs resulted in an average suppression
of 57.9   15.5% (17 suppressive clones repeatedly tested).
Figure 2. Tr1 cells can be differentiated from
CD25 CD4  T cells. CD4  T cells were puri-
fied, depleted of CD25  cells, and activated by
anti-CD3 mAbs cross-linked on CD32 
CD80 CD58  L-cells in the absence ( ) or
presence of IL-10 plus IFN- . After two
rounds of identical stimulation, T cells were re-
stimulated with immobilized anti-CD3 (10  g/
ml) and soluble anti-CD28 (1  g/ml) mAbs
and cytokine production was determined by in-
tracytoplasmic staining and cytofluorometric
analysis (A and B). In B the average percent positive cells from
five independent experiments is shown. * indicates a statisti-
cally significant difference in the percentage of cytokine pro-
ducing cells in cultures with IL-10 plus IFN- , in comparison
to those in the absence of cytokines. Error bars represent the
SEM. In parallel, polarized T cells were tested for their ability
to suppress the proliferation of naive autologous CD4  T cells
to alloantigens. Increasing numbers of cells which had been
differentiated in the absence ( ) or presence of IL-10 and
IFN-  were added to the primary MLR, and after 4 d of cul-
ture, [3H]thymidine was added for an additional 16 h. One
representative experiment is shown in C. Numbers above the
bars in cultures with IL-10 and IFN-  represent the percent
inhibition in comparison to the primary MLR alone. D repre-
sents the average reduction in proliferation of primary MLRs
induced by CD25 CD4  T cells differentiated in IL-10 and
IFN-  in five independent experiments. * indicates a statisti-
cally significant (P   0.05) reduction in proliferation in com-
parison to primary MLRs in the absence of T cells differenti-
ated in IL-10 and IFN- .1340 Human CD25 CD4  T Cell Clones
Similarly, when activated with soluble anti-CD3 mAbs and
APCs, an average suppression of 53.8   18.5% (15 sup-
pressive clones repeatedly tested) was observed.
Interestingly, only those clones which were (a) anergic,
(b) did not proliferate in response to cytokines, and (c) dis-
played a constitutively high expression of CD25, had a sup-
pressive phenotype. When the MFI and percent suppres-
sion of proliferation in response to immobilized anti-CD3
mAbs were plotted, there was a strong linear correlation
between suppressive capacity and expression of CD25 (Fig.
4 C). Furthermore, separation of the CD25 CD4  T cell
clones into suppressive and nonsuppressive groups revealed
that the MFI of CD25 staining was significantly higher in
the group with suppressive activity (P   0.000007). Lack
of proliferation in response to anti-CD3 mAbs was a less
reliable predictor of suppressive capacity, as several clones
within the nonsuppressive category were anergic (Fig. 4, A
and B). Therefore, the previously reported correlation be-
tween anergy and suppression is not absolute (37).
Suppressive Activity Is Not Conferred by High Constitutive
Expression of CD25. This strong correlation between ex-
pression of CD25 and suppressive activity raised the ques-
tion of whether high levels of CD25 alone may be suffi-
cient to confer suppressive function. We have previously
shown that activated effector CD4  T cells expressing high
levels of CD25 do not suppress proliferation (19); however,
the possibility remained that in these cells CD25  could be
down-regulated during the coculture. We therefore trans-
duced several nonsuppressive clones derived from either
CD25  or CD25 CD4  T cells with retroviral vectors en-
coding NGFR, as a marker gene, and with or without
CD25 under control of the LTR. Transduced cells were
purified by sorting for NGFR-positive cells, and subse-
quently analyzed for expression of CD25 in the resting
phase (Fig. 5 A). T cell clones which were transduced with
the LCD25-S N vector displayed significantly higher ex-
pression of CD25 than untransduced cells, or cells trans-
duced with the control LX-S N vector. Importantly, the
MFI of CD25 in the LCD25-S N–transduced cells was
equivalent to the levels of CD25 expressed by the suppres-
sive clones (Fig. 5 A). The transduced T cell clones were
then tested for their suppressive capacity. As shown in Fig.
5 B, expression of high levels of CD25 was not sufficient to
confer suppressive capacity. It is interesting to note that
neither nonsuppressive, nor anergic clones, acquired sup-
pressive capacity upon enforced expression of CD25.
Expression of CTLA-4 and GITR on CD25 CD4  T Cell
Clones. It has been reported that polyclonal populations
of CD25 CD4  T cells constitutively express high levels
of CTLA-4 and GITR (14–17, 19). It was therefore of in-
terest to determine whether expression of these two mole-
cules correlated with suppressive activity of the T cell
clones. FACS® analysis revealed that there was an abso-
lute correlation between constitutive expression of both
Figure 3. Isolation and characteriza-
tion of human CD25 CD4  T cells at
the clonal level. CD4  T cells were iso-
lated from PBMCs, stained with anti-
CD4 and anti-CD25 mAbs, and sepa-
rated into CD25 CD4  and CD25 
CD4  T cells by FACS® sorting to a
purity greater than 98 and 99%, respec-
tively (A). Resting T cell clones were
stained with anti-CD4 and -CD25
mAbs 12–14 d after the last restimula-
tion. Numbers on the top left indicate
clone number, and on the top right the
MFI and percent positive cells (B).
Resting T cell clones were also tested
for their ability to proliferate in response
to anti-CD3 mAbs (10  g/ml) in the
absence or presence of IL-2 (100 U/ml;
C), or in response to IL-2, IL-15 (10
ng/ml), or IL-2 and IL-15 together. (D)
After 48 h of culture, [3H]thymidine
was added for an additional 16 h. For
B–D results are representative of at least
five independent tests.1341 Levings et al.
CTLA-4 and GITR and suppressive capacity. Two repre-
sentative clones from the nonsuppressive (no. 6 and 87) and
suppressive groups (no. 19 and 21) are shown in Fig. 6. Of
the 10 clones tested, suppressive CD25 CD4  T cell
clones expressed four- to sixfold higher levels of both mol-
ecules. For CTLA-4, the MFI of the suppressive T cell
clones was 14.3   5.1, in comparison to 3.9   0.9 for
nonsuppressive clones (P   0.006). For GITR, the MFI of
the suppressive T cell clones was 36.6   12.0, in compari-
son to 7.4   1.9 for nonsuppressive clones (P   0.003).
We showed previously that neutralizing anti-CTLA-4
mAbs did not affect suppression mediated by CD25 
CD4  T cells (19). In the present study we investigated
whether GITR may play a role in suppression mediated by
human CD25 CD4  T cells. Experiments performed with
polyclonal populations of CD25 CD4  T cells revealed
that a commercially available monoclonal anti-GITR mAb
Figure 4. Suppression of naive T cell responses by CD25 CD4  T cell
clones. Autologous CD4  T cells were purified and activated with anti-
CD3 mAbs and irradiated CD3-depleted APCs (A) or anti-CD3 mAbs
immobilized on plastic (B) in the absence or presence of CD25 CD4  T
cell clones added at a 1:1 ratio. After 48 (A) or 72 h (B) of culture,
[3H]thymidine was added for an additional 16 h. Results are representa-
tive of 2–5 independent tests for each clone. In C, the MFI of 27 individ-
ual CD25 CD4  T cell clones and the respective percent reduction in
proliferation of autologous T cells activated with immobilized anti-CD3
mAbs in the presence of CD25 CD4  T cell clones were plotted.
Figure 5. Constitutive expression of CD25 does not confer suppressive
capacity. Nonsuppressive T cell clones derived from CD25 CD4  T cells
(clone #3) or CD25 CD4  T cells (clones #2, 21, 26, 75) were trans-
duced with LCD25-S N or a control vector, LX-S N. Transduced cells
were purified by FACS®-sorting for NGFR-positive cells. During the
resting phase, transduced cells were tested for expression of CD25 (A).
Pure populations of NGFR-positive cells transduced with LCD25-S N
or LX-S N, and their untransduced counterparts were then tested for
their ability to suppress the proliferation of naive CD4  T cells (1:1 ratio)
in response to immobilized anti-CD3 mAbs (B). After 72 h of culture,
[3H]thymidine was added for an additional 16 h. Results are representa-
tive of two independent tests for each clone.1342 Human CD25 CD4  T Cell Clones
(R&D Systems) did not reverse anergy or suppression (data
not depicted). Furthermore, addition of rGITR ligand at
concentrations of up to 100 ng/ml also had no effect on
anergy or suppression (data not depicted). Thus, similar to
CD25, CTLA-4 and GITR are cell surface markers for
suppressive CD4  T cells. However, it remains unclear
whether any of these molecules are functionally im-
portant.
Cytokine Production Profile of Suppressive CD25 CD4  T
Cell Clones. To further investigate whether CD25 CD4 
T cells may be related to IL-10–producing Tr1 cells, we
determined the cytokine production profile of the CD25 
CD4  T cell clones. A number of suppressive and nonsup-
pressive CD25 CD4  T cell clones were stimulated with
anti-CD3 and anti-CD28 mAbs and supernatants were as-
sayed for the presence of IL-2, IL-4, IL-5, IL-10, IFN- ,
and TGF- . As shown in Table I, nonsuppressive clones
varied in their cytokine production profile and tended to
produce significant levels of most cytokines tested. This
Th0-like phenotype of cytokine production was expected
from CD4  T cells which had been randomly cloned in
the absence of polarizing cytokines, such as IL-4 or IL-12.
In striking contrast, all suppressive CD25 CD4  T cell
clones consistently failed to produce detectable levels of
IL-2 or IL-10. The majority of the suppressive CD25 
CD4  T cell clones also did not produce significant
amounts of IL-4, IL-5, or IFN- . In contrast, all the sup-
pressive CD25 CD4  T cell clones produced significant
levels of active TGF- .
Cytokine production by suppressive CD25 CD4  T
cell clones was also investigated after activation with anti-
CD3 and anti-CD28 mAbs in the presence of exogenous
IL-2 (i.e., under conditions in which they proliferated).
Even when activated in the presence of IL-2, all suppres-
sive CD25 CD4  T cell clones failed to produce detect-
able levels of IL-10 (data not depicted). Under these condi-
tions, the levels of IL-4 and IL-5 produced by suppressive
CD25 CD4  T cells increased slightly, but always re-
mained significantly lower than those produced by nonsup-
pressive clones. Production of IFN-  and TGF-  by sup-
pressive CD25 CD4  T cell clones remained unchanged
when activated in the presence of IL-2 (data not depicted).
These data indicate that naturally occurring CD25 
CD4  T cells isolated from peripheral blood are not IL-
10–producing Tr1 cells. The fact that TGF-  was the only
cytokine which was consistently detected in the superna-
tants of all the suppressive CD25 CD4  T cell clones
suggests that naturally occurring CD25 CD4  T cells
may be more related to the TGF- –producing Th3 cells
which were originally described in models of oral tol-
erance (4).
Figure 6. Expression of CTLA-4 and GITR on CD25 CD4  T cell
clones. Several CD25 CD4  T cell clones were tested for expression of
intracytoplasmic CTLA-4 and cell surface GITR by flow cytometric
analysis (thick lines). Thin lines represent staining with the appropriate
control Abs. Clones 6 and 87 are representative of nonsuppressive clones,
and clones 19 and 21 of anergic and suppressive clones. Results are repre-
sentative of two independent tests for each clone.
Table I. Cytokine Production Profile of CD25 CD4  T 
Cell Clones
IL-2 IL-4 IL-5 IL-10 IFN-  TGF- 
CD25 CD4 
clone no. Nonsuppressive
pg/ml pg/ml ng/ml pg/ml ng/ml pg/ml
2  20 1,184 35.39 140 2.70 251
3  20 8,002 3.45 26 0.79 242
6  20 57 0.88  20 0.14 113
85  20 521 7.89 94 1.46 214
86 394 537 3.86 62 11.94 n.t.
87  20 419 2.96 262 4.17 114
89 476 604 4.26 183 8.77 n.t.
90 1,360 618 4.59 199 12.64 n.t.
Suppressive
4  20  20  0.02  20  0.06 151
17  20 67 0.05  20 0.07 186
18  20  20  0.02  20 n.t. 274
19  20 140 0.28  20 0.10 351
20  20  20  0.02  20  0.06 83
21  20  20  0.02  20  0.06 298
22  20  20  0.02  20  0.06 401
29  20  20  0.02  20  0.06 291
40  20  20  0.02  20  0.06 243
42  20 83 0.19  20 0.20 355
57  20  20  0.02  20 0.10 278
T cell clones were activated with  CD3 and  CD28 mAbs, and
supernatants were collected after 24 (for IL-2), 48 (for IL-4, IL-5, IL-10,
and IFN- ), and 72 h (for TGF- ). Amounts of cytokines in the
supernatants were determined by capture ELISA and/or CBA assay as
described in Materials and Methods. n.t.: not tested. Numbers represent
the average values obtained in 2–6 individual tests for each clone. SDs
were  20%. Clones were divided into suppressive and nonsuppressive
groups based on results obtained from experiments performed as
described in Fig. 4.1343 Levings et al.
Human CD25 CD4  T Cells Do Not Express Membrane-
bound TGF- . Recently, it has been reported that mu-
rine CD25 CD4  T cells and human CD25 CD4  thy-
mocytes express high levels of TGF-  bound to their
plasma membrane by an unknown mechanism (31, 32).
We therefore investigated whether human CD25 CD4  T
suppressor cell clones may also express this molecule in a
membrane-bound form. When expression of membrane-
bound TGF-  was analyzed on CD25 CD4  T cells
present in total PBMCs, by triple-staining with anti-CD4,
-CD25, and -TGF-  mAbs, no positive signal was de-
tected (Fig. 7 A, left panel). In addition, in CD25  and
CD25 CD4  T cells freshly isolated and purified by
FACS® sorting, no significant expression of membrane-
bound TGF-  was detected (Fig. 7 A, middle panel). Fur-
thermore, none of the CD25 CD4  T cell clones tested
expressed significant levels of membrane-bound TGF- 
(Fig. 7 B). However, it should be noted that in CD25 
CD4  T cells purified by positive selection using magnetic
beads, TGF-  appeared to be present on the cell surface
(Fig. 7 A, right panel). This false positive staining in
MACS-sorted cells was due to the fact that the primary
chicken-anti-TGF-  Ab nonspecifically bound to micro-
beads attached to cells purified by positive selection (Fig. 7
A, right panel, and data not depicted).
TGF-  Is At Least Partially Required for Suppressive Effects
of Human CD25 CD4  T Cell Clones. The Th3-like cy-
tokine production profile of the suppressive CD25 CD4 
T cell clones prompted us to test whether TGF-  was re-
quired for their suppressive effects. We therefore per-
formed suppression experiments using immobilized anti-
CD3 mAbs as a stimulus in the presence of neutralizing
anti–TGF-  mAbs. As expected, addition of anti–TGF- 
mAbs to naive CD4  T cells alone resulted in a slight in-
crease in proliferation (Fig. 8). In contrast, addition of anti–
TGF-  mAbs to the suppressive CD25 CD4  T cell
clones had no effect on their failure to proliferate in re-
sponse to anti-CD3 mAbs (data not depicted). When the
naive CD4  T cells were cocultured with suppressive
CD25 CD4  T cell clones, a significant reversal of sup-
pression was consistently observed in the presence of the
anti–TGF-  mAbs. Neutralizing anti–TGF-  mAbs re-
duced the suppressive capacity of the six CD25 CD4  T
cell clones tested by an average of 19.5   8.4% (P   0.02).
As expected, anti–TGF-  mAbs did not significantly affect
the proliferation of nonsuppressive CD25 CD4  T cell
clones in the absence (data not depicted) or presence of na-
ive CD4  T cells (Fig. 8). Similar experiments were per-
formed in the presence of anti–IL-10R mAbs, which had
no measurable effect on the suppressive capacity of the
CD25 CD4  T cell clones. Furthermore, when both anti–
IL-10R and –TGF-  mAbs were added in the suppression
experiments, results were not significantly different from
those with anti–TGF-  mAbs alone (data not depicted).
Figure 7. Human CD25 CD4  T cells or T cell clones do not express
membrane-bound TGF- . Total PBMCs were stained with anti-CD4,
-CD25, and -TGF-  Abs. CD25 CD4  or CD25 CD4  T cells were
gated, and expression of TGF-  (thick line) on the two subsets was com-
pared with staining by the secondary reagent alone (thin line; A, left
panel). In parallel, CD25 CD4  and CD25 CD4  T cells were purified
by FACS® sorting or via positive-selection with microbeads. Purified
populations were subsequently stained with anti–TGF-  Abs (thick line)
or with the secondary reagent alone (thin line). Results are representative
of nine independent experiments. For B, several CD25 CD4  T cell
clones were tested for expression of membrane-bound TGF- . Clone 87
is representative of nonanergic clones, clone 3 of anergic, nonsuppressive
clones, and clone 42 of anergic and suppressive clones. Results are repre-
sentative of two independent tests.
Figure 8. Partial requirement for TGF-  in suppression mediated by
CD25 CD4  T cell clones. Suppressive and nonsuppressive T cell clones
were tested for their ability to reduce proliferation of naive CD4  T cells
in response to immobilized anti-CD3 mAbs in the absence or presence of
neutralizing anti–TGF-  mAbs (1D11, 10  g/ml). After 72 h of culture,
[3H]thymidine was added for an additional 16 h. Numbers above the bars
indicate percent reduction in proliferation in comparison to naive CD4 
T cells without or with the mAbs.1344 Human CD25 CD4  T Cell Clones
Discussion
We analyzed naturally occurring human CD25 CD4 
T cells at the clonal level and investigated their possible re-
lationship with IL-10–producing Tr1 cells. Together, our
data strongly support the conclusion that these two types of
regulatory cells are distinct, and that CD25 CD4  T cells
do not represent the anergic precursors of IL-10–producing
Tr1 cells. Unlike Tr1-cell clones (12), suppressive CD25 
CD4  T cell clones express significantly higher levels of
CD25 in comparison to nonsuppressive controls, do not
proliferate in response to cytokines, and most importantly
do not produce IL-10. However, suppressive CD25 
CD4  T cell clones do produce TGF- , and this molecule,
although not bound to the cell membrane, had a small,
but significant role in suppression of proliferation. Fur-
thermore, characterization at the clonal level of CD25 
CD4  T cells demonstrates that human CD25 CD4  T
cells are not a homogenous population of suppressor
cells.
Studies on IL-10–induced antigen-specific unrespon-
siveness and differentiation of IL-10–producing Tr1 cells
revealed that CD25  T cells were dispensable for these im-
munomodulatory effects of IL-10. These data are in line
with our previous observation that Tr1 cells arise from
CD45RO-CD4  T cells (19), whereas CD25 CD4  T
suppressor cells are CD45RO  (18). These findings sup-
port the hypothesis that a major difference between Tr1
and naturally occurring CD25 CD4  T cells is that
whereas CD25 CD4  T cells exit the thymus as fully dif-
ferentiated suppressor cells (6), Tr1 cells can arise from any
naive peripheral CD4  T cell which encounters its antigen
in a tolerogenic fashion (3).
It has been previously reported that human CD25 
CD4  T cells could be split into suppressive and nonsup-
pressive fractions by sorting CD25bright and CD25dim cells,
respectively (21). In the present study, analysis at the
clonal level revealed that even the small fraction of
CD25brightCD4  T cells was not a homogenous population
of suppressor cells. Only 20 out of 44 (45%) CD25 CD4 
T cell clones which expressed high levels of CD25 were
consistently found to be suppressive. However, no conclu-
sions about the absolute frequency of suppressive cells
within the CD25bright population should be drawn, as the
process of cloning and selection of proliferating cells is
likely to bias against suppressive cells, which proliferate and
expand very poorly in comparison to nonsuppressive cells
(data not depicted).
The finding that the CD25bright subset of human CD4 
T cells is not a homogeneous population indicates that the
small fraction of suppressive cells must have a remarkably
potent suppressor effect. One should consider that the ma-
jority of reports on human cells are based on the use of
populations of CD25 CD4  T cells purified with mag-
netic beads, which contained mixtures of CD25dim and
CD25bright cells, but nevertheless were capable of potently
inhibiting proliferation and cytokine production by both
CD4  and CD8  T cells (18–20, 22–24). It remains to be
determined whether or not murine CD25 CD4  T cells
also represent a nonhomogenous population of suppressor
cells.
Suppressive CD25 CD4  T cell clones retain the bio-
logical properties which were previously described in
polyclonal populations. All suppressive T cell clones de-
rived from CD25 CD4  T cells failed to proliferate in re-
sponse to anti-CD3 mAbs in the absence of exogenous IL-
2, as described previously in both murine and human
CD25 CD4  T cells (1, 2, 18–20, 22–24). In addition,
unlike Tr1-cell clones which proliferate in response to cy-
tokines alone (12), all suppressive CD25 CD4  T cell
clones failed to proliferate in response to IL-2, IL-15, or
the combination of the two cytokines. This inability to re-
spond to IL-2 or IL-15 was not due to a lack of expression
of the IL-2R  or  c chains (data not depicted) and suggest
that suppressive CD25 CD4  T cells may have an intrin-
sic signaling defect. Importantly, suppressive CD25 CD4 
T cell clones inhibited the proliferation of CD4  T cells
in response to anti-CD3 mAbs both in the presence or
absence of APCs, further supporting the concept that
CD25 CD4  T suppressor cells have a direct effect on the
target T cells (6).
Suppressive and nonsuppressive clones derived from
CD25 CD4  T cells could be distinguished via analysis of
CD25, CTLA-4, and GITR expression since suppressive
function strongly correlated with persistent expression of all
three molecules. Experiments with nonsuppressive clones
transduced with retroviral vectors encoding CD25 revealed
that constitutively high levels of CD25 expression alone are
not sufficient to confer suppressive activity. The contribu-
tion of CTLA-4 toward the suppressive function is unclear.
Some reports demonstrated a role for this molecule (16, 17,
32), whereas others failed to do so (19, 21, 26). With re-
spect to GITR, more studies with well-characterized ago-
nistic and antagonistic Abs, and with the natural ligand, are
required to clarify its role in suppression. Although all
three of these molecules are markers for suppressive
CD25 CD4  T cells, even at the clonal level, they are not
specific since they are also expressed by activated CD4  T
effector cells.
The finding that suppressive CD25 CD4  T cell clones
do not produce IL-10 contrasts with several studies which
reported that freshly isolated human CD25 CD4  T cells
were capable of producing a number of cytokines, includ-
ing IL-10, when activated by alloantigens or polyclonal
stimuli (18–20, 22). The present data suggest that in previ-
ous studies performed with nonhomogeneous populations
of human CD25 CD4  T cells, the IL-10 was likely pro-
duced by nonsuppressive CD25  effector T cells. The ob-
servation that IL-10 does not have a role in the suppressive
capacity of CD25  clones is consistent with previous find-
ings that neutralizing anti–IL-10 mAbs failed to reverse
suppression of proliferation by polyclonal populations of
human CD25 CD4  T cells (18–20, 23, 24). These data
are also in accordance with the observation that murine1345 Levings et al.
CD25 CD4  T cells from mice genetically deficient for
IL-10 do not have an altered suppressive capacity (6). In in
vivo studies demonstrating a role for IL-10 in suppression
mediated by naturally occurring CD25 CD4  T cells (30,
38), IL-10 may not have been produced by the suppressive
fraction of CD25 CD4  T cells. Alternatively, it cannot be
ruled out that CD25 CD4  T cells may acquire the capac-
ity to produce IL-10 when stimulated under certain condi-
tions in vivo.
The observation that all the suppressive CD25 CD4  T
cell clones produced TGF- , and that this cytokine was in-
volved in their suppressive effects was somewhat more sur-
prising. Although it has previously been reported that poly-
clonal populations of human CD25 CD4  can produce
TGF-  (18, 19), reversal of suppression in the presence of
anti–TGF-  mAbs was never observed (18, 19, 23, 24).
Furthermore, CD25 CD4  T cells from mice genetically
deficient for TGF- 1 are fully suppressive, at least in vitro
(28). However, at the clonal level, we found a small ( 20%
reversal of inhibition), but consistent and statistically signif-
icant role for TGF-  in suppression of proliferation by all
suppressive CD25 CD4  T cell clones tested. It should be
noted that clonal analysis allowed us to investigate the sup-
pressive mechanism(s) in the absence of contaminating an-
ergic and/or effector CD25 CD4  T cells which may
have confounded analysis of polyclonal populations. Al-
though TGF-  may partially mediate the suppressive ef-
fects of CD25 CD4  T cells, it does not appear to be suffi-
cient, and therefore other suppressive mechanisms must
exist. Thus, in vivo, CD25 CD4  T cells may be able to
suppress T cell responses by a variety of mechanisms which
act in concert, and whose relative contribution may depend
on the microenvironment.
This partial requirement for TGF-  in suppression me-
diated by CD25 CD4  T cell clones contrasts with the
findings of Nakamura et al. who observed complete rever-
sal of suppression of proliferation by murine CD25 CD4 
T cells, using the same neutralizing mAb (31). In addition,
it has been reported that murine CD25 CD4  T cells and
human CD25 CD4  thymocytes express cell-surface
bound TGF-  (31, 32). We did not observe significant
staining for membrane-bound TGF-  on human CD25 
CD4  T cells isolated from peripheral blood. Further clari-
fication of the role of TGF-  in human cells awaits studies
with methods which allow specific and regulated abroga-
tion of TGF-  expression.
In conclusion, analysis of naturally occurring human
CD25 CD4  T cells at the clonal level revealed that these
cells are distinct from IL-10–producing Tr1 cells. This con-
clusion is supported by two recent reports which suggest
that one of the functions of CD25 CD4  T cells may be
to induce the differentiation of IL-10 and TGF- –produc-
ing Tr1 cells (39, 40). If true, this may clarify the confusion
surrounding the role of these cytokines in suppression me-
diated by CD25 CD4  T cells. The finding that freshly
isolated CD25 CD4  T cells from peripheral blood are
not a homogeneous population of suppressor cells has im-
portant implications for their further characterization, par-
ticularly for studies in which these cells are analyzed at the
molecular level. The use of human CD25 CD4  T cell
clones as a homogeneous population of suppressor cells will
help to reveal more specific markers, and ultimately gain a
better understanding of the factors which act in concert
with TGF-  to mediate their potent suppressive effects.
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